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Intraluminal aortic clamping has been achieved until now by means of a sophisticated device consisting of a three-lumen catheter
named Endoclamp, which allows at the same time occlusion of the aorta, antegrade delivering of cardioplegia, and venting through
the aortic root.This tool has shown important advantages allowing aortic occlusion and perfusate deliveringwithout a direct contact
with ascending aorta reducing meanwhile the risk of traumatic and/or iatrogenic injuries. Recently, a new device (Intraclude
catheter) with the same characteristics and properties has been proposed and introduced in clinical practice. The aim of this
paper is to investigate the differences between Endoclamp and Intraclude catheters and to analyze the advantages advocated by
this new device for intraluminal aortic occlusion since it is noticeable as these new technological tools are gaining more and more
attractiveness due to their appraised clinical efficacy.
1. Introduction
Since Bailey reported in 1951 the first surgical treatment
of mitral valve with mitral annulus narrowing by external
constriction through left thoracotomy [1], several approaches
and techniques for mitral valve surgery have been pro-
gressively proposed, modified, and refined, especially after
the introduction of CPB (cardiopulmonary bypass). LILLE-
HEI and colleagues reported the first case of mitral valve
repair through a right thoracotomy, using femoral artery
cannulation for cardiopulmonary bypass (CPB) [2]. With
extensive use of CPB in 1960s, median sternotomy became
the primary surgical approach to mitral valve considering
the undoubted advantages related to its reliability, speed,
and worthy exposure of the mitral valve as well as access to
the rest of the heart compared to right thoracotomic incision.
In the late 90s, the increasing interest for minimally invasive
surgery due to patients demand, marketing policy, and new
developing technologies stimulated the reconsideration of
different left atrial andmitral approaches. At first, parasternal
incision and partial sternotomy, following the work of Gilli-
nov and Cosgrove [3], have been themost popular minimally
invasive approach. More recently, in accordance with the
rule of courses and historical claims, the experimental works
performed in the laboratories at StanfordUniversity andNew
YorkUniversity have refocused the attention to right thoraco-
tomy leading to the development ofminithoracotomic video-
assisted or video-guided port-access approach [4].
This new technique exploited a peripheral perfusion and a
balloon catheter for aortic occlusion allowing a less invasive
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procedure through a mini thoracotomy (4–6 cm) approach
[5–7], with undoubted advantages related to an overall
reduction in surgical trauma, an effective improvement in
patient comfort, lower morbidities, and shorter in-hospital
stay, besides the remarkable cosmetic advantages especially
in women [8–10].
Due to materials and instrumentation improvements
different cannulation and aortic clamping strategies are
nowadays available:
(i) Full extra-thoracic CPB with external transthoracic
aortic clamping.
(ii) Full extra-thoracic CPB with endoaortic clamping.
(iii) Central arterial cannulation with external transtho-
racic aortic clamping.
(iv) Central arterial cannulation with endoaortic clamp-
ing.
Intraluminal aortic clamping has been achieved until now by
means of a sophisticated device consisting of a three-lumen
catheter named Endoclamp, which allows at the same time
occlusion of the aorta, antegrade delivering of cardioplegia,
and venting through the aortic root. This tool has shown
important advantages allowing aortic occlusion and perfusate
delivering without a direct contact with ascending aorta
reducing meanwhile the risk of traumatic and/or iatro-
genic injuries. Therefore, other than in less invasive surgery
procedures, the Endoclamp can be successfully adopted in
systematic surgery especially in presence of extensive calci-
fication of ascending aorta and in redo procedures allowing
safer cross-clamping without requirement for dissection and
manipulation of the ascending aorta and aortic root. Recently,
a new device (Intraclude catheter) with the same charac-
teristics and properties has been proposed and introduced
in clinical practice. The aim of this paper is to analyze the
differences between Endoclamp and Intraclude catheters and
to analyze the advantages advocated by this new device
for intraluminal aortic occlusion since it is noticeable as
these new technological tools are gaining more and more
attractiveness due to their appraised clinical efficacy.
2. Surgical Technique Using Endoclamp
Under general anesthesia, the patient is positioned in the
supine position, with slight elevation (30∘) of the right hem-
ithorax. All candidates for minithoracotomic video-assisted
or video-guided port-access approach are ventilated with a
double-lumen endotracheal tube in order to exclude, when
needed, right lung ventilation. Monitoring includes double
side arterial lines and use of TEE (Transesophageal Echocar-
diography). A small right mini thoracotomy (working port)
and two additional ports are performed as previously
described [4, 11–13]. Venous drainage is generally achieved
with double venous cannulation with a 14–20 Fr cannula
placed percutaneously, under transesophageal echocardio-
graphic guidance, through the internal jugular vein into the
superior vena cava and a cannula into the inferior vena (Fr)
cava through the femoral vein using Seldinger technique.
Figure 1: Endoaortic balloon correct placement.
Figure 2: TEE monitoring of balloon position.
Arterial cannulation is performed with placement under
direct vision into the femoral artery of a dedicated 21–23 Fr
cannula (Endoreturn), a Y-shaped device with a side branch
that allows the introduction of the occlusion balloon. The
Endoclamp endoaortic balloon is at this time placed from the
Endoreturn cannula side branch, under TEE guidance, in the
ascending aorta just above the sinotubular junction (Figures
1 and 2).
The Endoclamp is a 10.5 Fr, 100 cm long, three-lumen
catheter with an elastomeric balloon near its tip customized
for endoluminal occlusion of the ascending aorta in order to
separate the aortic root from arterial circulation. The surface
contact of the balloon with the aortic wall is limited to 10mm
in length to avoid coronary occlusion during cardioplegia
delivery. The large central lumen of the catheter attends two
functions: delivery of cardioplegic solution during occlusion
and venting from the left cardiac chambers both through
the aortic root. The two remaining lumens are designed
to serve as conduits for balloon inflation and aortic root
pressure monitoring throughout the cardiac arrest. After
proper position of the device, CPB is instituted and, under
TEE monitoring to avoid balloon migration, the endoaortic
balloon is progressively inflated with careful attention to
its position at the level of the sinotubular junction [14].
Once its correct position is ascertained the cardioplegic
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solution is administered via an antegrade route. Using this
technique blood pressure through the arterial line should be
continuously monitored in order to promptly detect possible
modifications that might be suggestive of partial or transient
occlusion of the arterial arch vessels. In our experience the
balloon should initially be inflated using an amount of saline
solution proportional to the diameter of the sinotubular
junction (1 : 1) to avoid unnecessary overexpansion. The
balloon pressure is continuously monitored to reach and
maintain a target pressure of around 350/400mmHg. It is
important to remember that during the cardiac arrest the
Endoclamp pressure can progressively decrease by 10–20%
due to the variation of temperature and the reduced stiffness
of the aortic wall. In this case, no additional volume of
intraballoon saline is needed if the heart is asystolic and
the field is dry. The adhesion of the balloon with the aortic
wall is crucial for steadiness of the device. Usually a balance
is achieved because the balloon is pushed downstream by
arterial flow from femoral arterial cannula and upstream
by the pressure originated inside the root by cardioplegia
delivery or by the systolic ejection from the heart before
complete cardiac arrest. In presence of trivial aortic regurgi-
tation and/or inadequate drainage of the left ventricle with
unsatisfactory cardiac arrest during the antegrade cardio-
plegic induction, adenosine injection directly in the aortic
root can be used to facilitate heart arrest and therefore
facilitate the correct endoclamping function. In addition, to
optimize left ventricular drainage, an Endopulmonary Vent
Catheter, previously inserted by anesthesiologist through
central vein access, can be usedwhen needed. During surgery
continuous TEE monitoring is recommended, to provide
an optimal monitoring of venous cannula position, deairing
maneuvers, and, certainly, an assessment of valve function
after the operation [15, 16]. Other indirect monitoring tools
include NIRS (INVOS) or transcranial Doppler [17] both
able to detect any functional impairment of cerebral blood
flow [18] caused by balloon migration. Once the surgical
procedure has been completed, the balloon is deflated and
partially withdrawn. At this time aortic venting is achieved
through the same sideline of the catheter. After weaning
from CPB, the device is fully removed through the side
branch of the Endoreturn arterial cannula. A major concern
of this technique with adoption of this device is the possible
reduction of the arterial cannula lumen after introduction
of the endoluminal balloon. Although this phenomenon is
unusual with a 23 Fr cannula it has been described with the
21 Fr size with possible negative impact on systemic perfusion
or in safety of CPB management. The reduction of the
arterial cannula lumen related to the steric hindrance of the
Endoclamp catheter can, in fact, result in an elevated pressure
on the line of arterial perfusion (>250mmHg), especially
in cases of small and elastic femoral arteries, like in young
women with small body surface area or in patients with
severe atherosclerotic disease of the iliac-femoral tree. In our
experience, with pressure >300mmHg during full flow CPB,
a contralateral femoral arterial cannulation, even with a small
(18-19 Fr) cannula, is advisable by means of a double Y line
perfusion to avoid malperfusion or complication on CPB
lines or oxygenator.
3. Pitfalls
Although most of studies showed the feasibility and safety of
minimally invasive mitral valve surgery using the endoaortic
clamping technique [19–21], several specific issues emerged
from data reported in literature. Particularly in first series,
multiple severe complications have been described, such
as aortic dissection or iliac artery injury [22], probably
due to first generation stiffer catheters, worse monitoring
techniques, and learning curve of the operator. In fact,
originally Endoclamp position monitoring was performed
using fluoroscopy only during the positioning of the device
without any further control during the surgical procedure
and, moreover, surgeons were not enough skilled to manage
catheters and guide-wires. Nowadays severe vascular com-
plications are very rare and cannot be considered a specific
burden of endoluminal clamping technique itself [23, 24].
Concerning generic complications some authors and
especially the ISMICS (International Society for Minimally
Invasive Cardiothoracic Surgery) summit claimed an aug-
mented risk for cerebrovascular events, hypothetically due
to greater use of femoral arterial cannulation for CPB.
Plaque embolization during catheter introduction into the
femoral artery or related to retrograde perfusion as well
as traumatic injuries with consequent artery dissection or
pseudoaneurysms formation and epiaortic vessel obstruction
caused by balloon migration are well known complications
[25–27] limited in more recent practice by the adoption of a
more careful monitoring and dedicated catheter and devices.
Furthermore, another pitfall can be related to insertion
of the endoluminal balloon into the arterial cannula that in
some cases can induce increased resistance in the arterial line
requiring a double arterial cannulation [28].
Other possible complications, described particularly in
the first “era,” are directly related to the endoluminal bal-
loon device. Retrograde aortic dissection, balloon migration,
balloon caught by suture for proximal anastomosis in coro-
nary surgery, and balloon perforation during mitral valve
procedure have been described and reported in literature
[29]. Other authors, despite the overlapping results between
classical sternotomy technique and port-access technique
using Endoclamp, described cases that required switching to
external cross-clamping to solve the unexpected problems
arisen with endoluminal balloon [30].
4. Intraclude Improvements
In this milieu a novel device, the Intraclude catheter, has
been designed and approved for clinical use to overcome
and solve these issues. Intraclude is a three-lumen catheter
designed as an evolution with the same purposes of the
Endoclamp. Innovations of this device compared to the
Endoclamp are related particularly to the catheter size. New
developed technology permitted, in fact, reducing the size of
the device from 10.5 Fr to 9.5 Fr leading to the attainment
of decreased resistances through the arterial cannula and,
therefore, allowing a major blood flow at minor pressures,
with consequent limitation of the stress and the so called
“sand blast effect” related to the high-pressure blood jet.
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Some authors reported occasionally experiences of catheter
“kinking,” probably due to the minor caliber and softer
material with respect to Endoclamp.This phenomenon is not
frequent since the reduced caliber of the tip of Intraclude
compared to the proximal part (hub) that maintains a
diameter of 10.5 Fr is specifically designed to avoid the risk
of kinking or twisting of the catheter and consequently to
prevent the hazard of high pressure during cardioplegia deliv-
ering. Femoral artery injury or pseudoaneurysm formation
leading to limb ischemia could be complications of femoral
cannulation itself, regardless of the endoaortic balloon use,
and prevention strategies are described elsewhere [27, 31].
Concerning balloon migration, Intraclude has a different
shaped balloon with wider cylindrical-shape compared to
the spherical balloon of the Endoclamp with advantages in
terms of surface contact that is increased from 10mm to
18mm. This change is supposed to ameliorate the stability
of the endoluminal balloon with a better “fitting” into the
aortic lumen and improved adhesion to the aortic wall
allowing a more reliable sealing after inflation and therefore
reducing the incidence of dislocation and/or blood leak into
the ascending aorta.
To further ameliorate safety and performance of the
endoluminal clamping, the Intraclude shaft is curve-shaped,
allowing a better adhesion to the aortic arch and a perfect
tip orientation towards the aortic valve for the cardioplegia
delivery. Moreover, this curvature is supposed to avoid the
“slack effect” experienced with the straight Endoclamp shaft
limiting the possible migration of the balloon toward the
aortic valve due to the tension generated by the catheter
bended into the aortic arch.
The different balloon shape also allows the availability
of a wider range of calibers, ranging from 20 to 40mm,
rather than the Endoclamp limited to a range of 20–38mm.
Dealing with balloon disruption or perforation, continuous
TEEmonitoring is essential to avoidmalposition and prevent
accidental perforation of the balloon during mitral valve
surgery as well described in literature [14]. To prevent
spontaneous ruptures, the inflation volume has been reduced
to 35mL (from 40 of Endoclamp), preventing in this way
either possible clamp failure, or balloon migration. In this
regard, it is useful to keep in mind that pressure variations
throughout the surgical procedure can lead to migration of
the device as well as that migration itself can determine
pressure change with vicious cycle mechanism.
In a recent analysis conducted by several European
surgeons [32], the routine adoption of Intraclude device
has been considered as one of the key factors leading to a
significant reduction of morbidity and complications with
particular emphasis concerning the stroke rate incidence.
5. Discussion
Minimally invasive surgical treatment of valvular heart dis-
ease has steadily increased over the last several years becom-
ing an established technique with high successful outcome in
many specialized centers. The vast majority of larger clinical
studies demonstrate that minimally invasive valve surgery
using the port-access approach after an initial learning curve
Figure 3: Excellent visualization of the mitral valve by Thru-Port
System.
[19, 20, 33–36] is a safe and effective approach in terms
of short- and long-term results, mainly for redo opera-
tions and even for elderly patients with moderately elevated
perioperative risk. Furthermore this technique has shown
a low morbidity and mortality achieving functional and
echocardiographic outcomes comparable to those obtained
with conventional surgery. Measurable patient benefits from
case-matched control trials [37–39] include less pain, less
blood transfusions, fewer wound infections and pulmonary
complications, and faster recovery as well as a better cosmetic
result. Moreover recent improvements in Thru-Port systems
offer excellent visualization of cardiac structures (Figure 3)
through a virtually bloodless, unobstructed operative field
without any increase of operative difficulty, procedure, and
pump times, thus consenting to adopt successfully the same
well established surgical techniques through the smallest
incision possible.
In this setting the new device Intraclude undoubtedly
improved safety and properness of intraluminal aortic occlu-
sion duringminimally invasivemitral surgery.The preshaped
curved silhouette, the reduced diameter, and the cylindri-
cal balloon profile have shown unquestionable advances
allowing an easier and more reliable endoartic clamping
with positive impact in terms of reduced stroke incidence
suggesting a spreader use of this device other than in
minimally invasive surgery. New catheter Intraclude has been
introduced in the European market in 2012, replacing the old
catheter Endoclamp. Since then, more than 2500 catheters
have been used in Europe for ascending aorta occlusion
and cardioplegia delivering during minimally invasive mitral
valve surgery.
In our experience, we used the catheter Endoclamp from
2000 in our patients in more than 600 operations. We moved
to use the new device, Intraclude, from the beginning, in
our patients and we performed more than 60 cases with
this device. At the beginning of the experience, we had
some concerns regarding the extreme softness of the catheter
with some risk of twisting and kinking. Nevertheless, we
immediately appreciated, with respect to Endoclamp, the
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fact that its reduced size allowed a minor increase in the
arterial line pressure during perfusion. Using Endoclamp we
experienced at least five cases of migration of the balloon
toward aortic valve and left ventricle. We did not have similar
cases with Intraclude probably due to wider adhesion of
this balloon to the aortic wall. The preshaped curvature of
Intraclude makes its position easier in contact with the aortic
arch reducing the need of additional maneuvers to avoid
slack of catheter in thoracic aorta. From our experience,
during introduction of the device it is mandatory to avoid any
twisting of the curvature before the tip of the catheter reaches
the root of ascending aorta.We had four cases of spontaneous
rupture of Endoclamp but none using Intraclude. This could
be related to the different shape of the balloon and/or to
the material of this new device that seems to be helpful in
terms of strength and fitting of the balloon with irregularities
of the aortic wall. In conclusion we firmly believe all these
technological developments and tools applied to minimally
invasive procedure have gained, over time, more and more
attractiveness due to their appraised clinical efficacy, and
the acquired clinical experience in thousands of patients
worldwide has led to a global improvement and to an imple-
mentation of this promising and ground-breaking surgical
approach. In brief we are facing a gradual process where
something changes into a different and usually more complex
or better form, which simply means evolution.
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